

Amendments to the Claims

This listing of claims will replace all prior versions of the claims and listing of the claims in the application.

Listing of Claims**1-94. (Cancelled)**

95. **(Currently Amended)** A therapeutic composition, comprising an isolated polypeptide selected from the group consisting of:

(a) an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:6; and

(b) an isolated polypeptide about 30 amino acid residues in length and comprising at least a portion residues 14-39 of SEQ ID NO:6, or an epitope-containing portion thereof; the sequence of (a) which comprises at least one epitope of the polypeptide of (a), wherein the portion is selected from the group consisting of

~~Fel 16 (residues 1-22 of SEQ ID NO:6),~~

~~Fel 17 (residues 12-33 of SEQ ID NO:6)~~

~~Fel 32-1 (residues 12-24 of SEQ ID NO:6),~~

~~Fel 32-2 (residues 14-24 of SEQ ID NO:6),~~

~~Fel 32-3 (residues 16-24 of SEQ ID NO:6),~~

~~Fel 18 (residues 23-48 of SEQ ID NO:6),~~

~~Fel 33-1 (residues 26-36 of SEQ ID NO:6),~~

~~Fel 33-2 (residues 26-38 of SEQ ID NO:6),~~

~~Fel 33-3 (residues 26-40 of SEQ ID NO:6),~~

~~Fel 31-1 (residues 14-40 of SEQ ID NO:6),~~

~~Fel 31-2 (residues 14-39 of SEQ ID NO:6),~~

~~Fel 31-3 (residues 14-38 of SEQ ID NO:6),~~

~~Fel 31-4 (residues 14-37 of SEQ ID NO:6),~~

~~Fel 31-5 (residues 14-36 of SEQ ID NO:6),~~

~~Fel 31-6 (residues 15-40 of SEQ ID NO:6),~~

~~Fel 31-7 (residues 15-36 of SEQ ID NO:6),~~

~~Fel 20-1 (residues 34-59 of SEQ ID NO:6),~~

~~Fel 25 (residues 49-68 of SEQ ID NO:6),~~

~~Fel 28 (residues 60-82 of SEQ ID NO:6);~~

~~or an epitope-containing portion thereof; and~~

~~(e) a modified form of a polypeptide of (a) or (b) comprising at least one epitope of the polypeptide of (a) or (b);~~

wherein said composition is capable of reducing an allergic response to a cat antigen in an individual sensitive to said antigen.

96. **(Currently Amended)** A composition according to claim 95 comprising a mixture of said polypeptides in (a)-(b) (e).

97-100. **(Canceled)**

101. **(Canceled)**

102. **(Currently Amended)** A polypeptide according to claim 95101, wherein the polypeptide has a stimulation index of at least 4.0 or a positivity index of at least 250, wherein the stimulation index is defined as the ratio of measured proliferation of T cells and antigen presenting cells from a responding individual when exposed to antigen, to the measured proliferation of said cells in the absence of antigen, and wherein the positivity index is defined as the average stimulation index of a population of responding individuals tested multiplied by the percentage of individuals in the population exhibiting a positive response.

103. **(Currently Amended)** A polypeptide according to claim 95101, produced recombinantly.

104. **(Currently Amended)** A polypeptide according to claim 95104, produced by chemical synthesis.

105-110. (Canceled)

111. **(Currently Amended)** An isolated polypeptide selected from the group consisting of:

(a) an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:6; and

(b) an isolated polypeptide ~~consisting of comprising at least a portion of the sequence of (a), wherein the portion is selected from the group consisting of:~~
~~Fel 17 (residues 12-33 of SEQ ID NO:6);~~
~~Fel 32-1 (residues 12-24 of SEQ ID NO:6);~~
~~Fel 32-2 (residues 14-24 of SEQ ID NO:6);~~
~~Fel 18 (residues 23-48 of SEQ ID NO:6);~~
~~Fel 31-1 (residues 14-40 of SEQ ID NO:6);~~
~~Fel 31-2 (residues 14-39 of SEQ ID NO:6);~~
~~Fel 31-3 (residues 14-38 of SEQ ID NO:6);~~
~~Fel 31-4 (residues 14-37 of SEQ ID NO:6); and~~
~~Fel 31-5 (residues 14-36 of SEQ ID NO:6).~~